Recently, GEM has nevertheless been reported to be active in TP53-aberrant or relapsed/refractory CLL [50], and a similar observation has also been published for CYT, including its effect in highly adverse Richter syndrome (CLL transformation to diffuse large B cell lymphoma) [51]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.